Crinetics Pharmaceuticals, Inc. (CRNX) Monday announced the appointment of Tobin Schilke as chief financial officer, effective February 28, 2025.
Schilke, with over 25 years of global pharmaceutical experience, had worked in several biotech companies, and most recently was with Revance Therapeutics as chief financial officer.
On March 10, 2025, Crinetics, a clinical stage pharmaceutical company, expects to grant Schilke 52,000 restricted stock units and a stock option to purchase 80,000 shares of common stock.
For comments and feedback: editorial@rttnews.com